Comment from Associate Prof. Gasinee Witoonchart, Rector of Thammasat University:
"Thammasat University has continued creating social innovation in all dimensions for the people and the future. As the economic development of recent years has caused an increase in the number of cancer patients, we are proud to bring this groundbreaking proton therapy system and look forward to providing people with advanced medical treatment."

Comment from Yohei Maeshima, President and CEO of Olba Healthcare:

"We position Thailand as the medical hub in the ASEAN region where the population is aging, and a point of development for our business in the ASEAN countries. Through the introduction of proton therapy, we aim to contribute to the healthy life span of the people and to become the bridge between Thailand and Japan in the medical field."

Comment from Takuji Furukawa, President and CEO of B dot Medical:
"The signing of this MOU is the first step toward global expansion for us, and signifies that B dot Medical's work is being recognized around the world. We look forward to working with Thammasat University on this innovative project to bring the advanced world-class cancer treatment to ASEAN countries, including Thailand."


About B dot Medical Inc.
B dot Medical is a startup company originating from the National Institute of Radiological Sciences (NIRS). The company has developed the "ultra-compact proton therapy system" utilizing the advanced technology and experience gained at NIRS. The company is challenging the world with Japanese technological innovation.

Back to HCB News

Rad Oncology Homepage